Listed by the USPTO as JADHAO, SAMADHAN JAISING
Tech Center 1600 • Art Units: 1648 1653 1671 1672
This examiner grants 46% of resolved cases
JADHAO, SAMADHAN JAISING is a USPTO patent examiner in Tech Center 1600 and Art Unit 1648. The profile reports 65 resolved cases, an allowance rate of 46.2%, and a median of 1331 days to allowance. The interview lift is 47.0%, which is slightly above the reported allowance-rate figure and forms a prominent part of the profile.
The listed companies are Denka Company Limited, THE GENERAL HOSPITAL Corporation, and The Governors of the University of Alberta. The listed firms are LEYDIG VOIT & MAYER, LTD, Meunier Carlin & Curfman LLC, and Baker Donelson. The 46.2% allowance rate provides an outcome reference, while the 1331-day median addresses timing. The 47.0% interview lift supports purposeful interview preparation, with the 65-case record defining the scope of the available evidence.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18273466 | T CELL-DIRECTED ANTI-CANCER VACCINES AGAINST COMMENSAL VIRUSES FOR TREATING MUCOSAL CARCINOMAS | Non-Final OA | The General Hospital Corporation |
| 18270131 | CROSS-NEUTRALIZING SARS-COV2 ANTIBODIES | Non-Final OA | California Institute of Technology |
| 18529858 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | The Governors of the University of Alberta |
| 17488384 | RAPID TEST SYSTEM FOR VIRAL AND BACTERIAL INFECTIONS | Final Rejection | The Cleveland Clinic Foundation |
| 17769940 | METHODS FOR ULTRASENSITIVE DETECTION OF PROTEIN AND CELLULAR BIOMARKERS | Final Rejection | GEORGIA TECH RESEARCH CORPORATION |
| 17612426 | DOSAGE REGIMENS FOR VACCINES | Final Rejection | Gilead Sciences, Inc. |
| 18249419 | BACULOVIRUS EXPRESSION VECTOR | Final Rejection | Intervet Inc. |
| 18040920 | Devices and Methods for Detection of Viruses from Exhaled Breath | Final Rejection | Northeastern University |
| 18461955 | MODIFIED POLYNUCLEOTIDES ENCODING THE SARS-COV-2 SPIKE PROTEIN FOR SAFER DESIGNS OF CORONAVIRUS VACCINES | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18988667 | ASSESSMENT AND TREATMENT OF CHRONIC HEPATITIS B | Final Rejection | BRII BIOSCIENCES, INC. |
| 18562078 | ANTI-NOROVIRUS ANTIBODY | Non-Final OA | Denka Company Limited |
| 18562099 | NOROVIRUS IMMUNOASSAY METHOD AND IMMUNOASSAY INSTRUMENT | Non-Final OA | Denka Company Limited |
| 18557787 | ENGINEERED INFLUENZA VIRUSES EXPRESSING SARS-COV-2 ANTIGENS, VACCINES AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | Duke University |
| 17782899 | PROCESS FOR PRODUCING A PROPHYLACTIC AND THERAPEUTIC DNA IMMUNOLOGICAL COMPOSITION FOR HPV AND CANCERS ASSOCIATED WITH THE VIRUS, HYBRID PROTEIN, EXPRESSION VECTOR, IMMUNOLOGICAL COMPOSITION AND USES THEREOF | Final Rejection | INSTITUTO BUTANTAN |
| 18026544 | CORONAVIRUS ANTIBODIES AND USES THEREOF | Non-Final OA | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES |
| 18150917 | METHOD FOR IDENTIFYING AND/OR REGULATING SENESCENCE | Non-Final OA | INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES |
| 18255539 | COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Gritstone bio, Inc. |
| 18043317 | MULTIVALENT NUCLEIC ACID BASED CORONAVIRUS VACCINES | Non-Final OA | CureVac SE |
| 18012838 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | Final Rejection | Lycia Therapeutics, Inc. |
| 17627170 | RECOMBINANTLY-MODIFIED ADENO-ASSOCIATED VIRUS HELPER VECTORS AND THEIR USE TO IMPROVE THE PACKAGING EFFICIENCY OF RECOMBINANTLY-MODIFIED ADENO-ASSOCIATED VIRUS | Non-Final OA | CHARLES RIVER LABORATORIES, INC. |
| 18278682 | ORAL COMPOSITIONS AND USE OF SAME IN VACCINATION | Non-Final OA | MIGVAX LTD. |
| 18546586 | REVERSE PEPTIDES FROM CORONAVIRUS FOR IMMUNOGENIC PURPOSES | Non-Final OA | Emergex Vaccines Holding Limited |
| 18002844 | ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND USES THEREOF | Non-Final OA | HUMABS BIOMED SA |
| 18275226 | S-RBD Trimer Protein Vaccine for Novel Coronavirus and Preparation Method and Application Therefor | Final Rejection | NATIONAL VACCINE AND SERUM INSTITUTE (NVSl) |
| 18254576 | MODIFIED HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN AND USE THEREOF | Final Rejection | Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences |
| 18259018 | SARS-CORONAVIRUS 2 NEUTRALIZING ANTIBODY | Non-Final OA | SCRIPPS KOREA ANTIBODY INSTITUTE |
| 18258676 | PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PROTOPARVOVIRUS AND AN ANTIVIRAL BENZIMIDAZOLE AND USES THEREOF FOR TREATING CANCER | Non-Final OA | Luxembourg Institute of Health |
| 18034933 | SPECIFIC REACTION MIXTURE FOR USE IN THE DIAGNOSIS OF COVID-19 WITH ISOTHERMAL AMPLIFICATION METHOD | Final Rejection | ISTANBUL MEDIPOL UNIVERSITESI |
| 18041025 | CORONAVIRUS POINT-OF-CARE AGGLUTINATION ASSAY | Final Rejection | Veravas, Inc. |
| 18018442 | RECOMBINANT VACCINIA VIRUS | Non-Final OA | Shiga University of Medical Science |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy46.2% of resolved applications examined by Samadhan Jaising Jadhao were allowed (65 resolved cases), compared with 49.6% across Art Unit 1648 over the last five years.
This examiner's interview lift is +47.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Samadhan Jaising Jadhao took 1,331 days on average from filing to allowance.
Samadhan Jaising Jadhao examines applications in Art Unit 1648 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
